|Bid||15.10 x 800|
|Ask||23.50 x 1000|
|Day's Range||14.93 - 16.06|
|52 Week Range||10.23 - 30.35|
|Beta (3Y Monthly)||3.64|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2017 - Nov 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.33|
# Accelerate Diagnostics Inc ### NASDAQ:AXDX View full report here! ## Summary * Bearish sentiment is high ## Bearish sentiment Short interest | Negative Short interest is extremely high for AXDX with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting AXDX. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $1.16 billion over the last one-month into ETFs that hold AXDX are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to firstname.lastname@example.org. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
TUCSON, Ariz., Jan. 2, 2019 /PRNewswire/ -- Accelerate Diagnostics announced today that the company is scheduled to present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019, at 2:30 PM Pacific Time. About Accelerate Diagnostics, Inc. Accelerate Diagnostics, Inc. (AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices Read More...
TUCSON, Ariz., Nov. 27, 2018 /PRNewswire/ -- Accelerate Diagnostics, Inc. has joined with Sepsis Alliance to celebrate #GivingTuesday, November 27th, a global day of giving that harnesses the collective power of individuals, communities and organizations to encourage philanthropy and to celebrate generosity worldwide. Accelerate Diagnostics has pledged to match the first $15,000 donated to Sepsis Alliance on #GivingTuesday to help raise awareness of sepsis as an often preventable medical emergency and improve outcomes for patients affected by sepsis through expanded healthcare provider education. Any infection can lead to sepsis, which is now the third leading cause of death in the United States.
Short interest is extremely high for AXDX with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting AXDX. ETFs that hold AXDX had net inflows of $1.54 billion over the last one-month.
Short interest is extremely high for AXDX with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting AXDX. Over the last one-month, outflows of investor capital in ETFs holding AXDX totaled $191 million.
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 6.82% and -53.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Tucson, Arizona-based company said it had a loss of 41 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Revenue Placements up 40 Percent in U.S., Total Revenue up 64 Percent TUCSON, Ariz. , Nov. 6, 2018 /PRNewswire/ -- Accelerate Diagnostics, Inc. today announced financial results for the quarter ending ...
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Short interest is extremely high for AXDX with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting AXDX. The net inflows of $1.30 billion over the last one-month into ETFs that hold AXDX are not among the highest of the last year and have been slowing.
TUCSON, Ariz. , Oct. 17, 2018 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that it will host a conference call on Tuesday, November 6, 2018 to review the company's third quarter 2018 financial ...
TUCSON, Ariz. , Sept. 27, 2018 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that Joan Martin resigned from his position as Executive Vice President and Head of Europe , Middle East , and ...